We are live on ! Find out more
OPNT

Opiant Pharmaceuticals, Inc. Common Stock
OPNT

Delisted

OPNT was delisted on the 1st of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Opiant Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

39.31% less ownership

Funds ownership: 39.31% → 0% (-39%)

100% less funds holding

Funds holding: 36 → 0 (-36)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $41.2M → $0 (-$41.2M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 35

Holders
–
Holders Change
-36
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
35
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WSL
Western Standard LLC
California
-$8.6M
2
ACA
Apis Capital Advisors
New York
-$4.34M
3
Morgan Stanley
Morgan Stanley
New York
-$4.01M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.87M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.97M

OPNT Hedge Fund Activity: Q1 2023 in Review

0 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2023, worth a combined $0 — down 100% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of OPNT and 0 opened new positions — a net loss of 35 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Western Standard LLC, exiting entirely with an estimated $8.6M sold.

  • 0 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2023, down from 36 in Q4 2022.
  • Funds reported $0 of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 35 closed out, a net change of -35 holders.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Western Standard LLC, an estimated $8.6M sold.

Based on aggregated 13F filings for Q1 2023.